Compare Twist Bioscience Corp (TWST) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Financial Select Sector SPDR Fund — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Financial Select Sector SPDR Fund trades at $57.29. Which is the better fit depends on your goals.
| TWST | XLF | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | — |
52-Week High | $153.10 | $58.55 |
52-Week Low | $24.16 | $47.80 |
Enterprise Value | $8.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
XLF, the Financial Select Sector SPDR Fund, trades at $57.3, down 1.38% over 24 hours. The technical outlook is neutral overall, with bullish moving averages but neutral oscillators, and key support at $57. Recent news highlights consolidation amid shifting interest rate expectations and fund manager rotation into financials in Q2 2026. The ETF offers exposure to 76 large-cap U.S. financial firms with a low expense ratio of 0.08%.
The outlook for XLF is balanced. Potential upside exists from rising interest rates benefiting banks and institutional inflows, but risks include economic sensitivity and sector volatility. The neutral technical and sentiment signals suggest a wait-and-see approach, with the dividend providing modest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
